Neoantigen-pulsed dendritic cells use CD80/CD86 to costimulate and prime neoantigen-specific T cells, which then kill tumor cells presenting the neoantigen–HLA via perforin/granzyme or Fas–FasL. The CD80/CD86+ dendritic cells themselves are not targeted for killing.